JPRN-UMIN000011604已完成未知
Anti-tumor effect and safety of GDP therapy (gemcitabine, dexamethasone, and cisplatin) in patients with relapsed or refractory non-Hodgkin lymphoma - Anti-tumor effect and safety of GDP therapy (gemcitabine, dexamethasone, and cisplatin) in patients with relapsed or refractory non-Hodgkin lymphoma
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Received a gemcitabine previously 2)Allergic experience to rituximab or mouse proteins in the case of administration of rituximab 3)Pulmonary fibrosis or interstitial pneumonia detected within 28 days 4)Serious heart disease 5)Serious digestive symptoms 6)Body cavity fluid requiring treatment 7)Severe bone marrow suppression 8)Active infection 9)Serologically positive for HBsAg, HCVAb, or HIVAb 10)Severe bleeding tendency 11)Symptomatic brain metastasis 12)Critical complication 13)Serious mental disease 14)Active malignancy concomitantly existed 15)Auto immune hemolytic anemia 16)Lactating women, pregnant women and women suspected of being pregnant 17)Disagreement on intercourse without contraception 18)Ineligibility owing to the decision of doctor involved in this trial
研究者
相似试验
Unknown
2 期
GDP in Frontline Chemotherapy for Patients With PTCL-NOSLymphoma, T-Cell, PeripheralNCT02404571Chinese Academy of Medical Sciences28
招募中
3 期
Cross over trial of GD and GP therapy in metastatic urothelial carcinoma after the failure of cisplatin-based chemotherapy: randomised phase 3 trialsmetastatic urothelial carcinoma patients after the failure in the cisplatin-based first line systemic chemotherapyJPRN-UMIN000018517agoya City University Graduate School of Medical Sciences60
已完成
2 期
Phase II trial of GDP therapy (gemcitabine, cisplatin and dexamethasone) in patients with refractory or recurrence non-Hodgkin's lymphoma having a history of more than 2 regimens.non-Hodgkin's lymphomaJPRN-UMIN000013588Kyoto Prefectural University of Medicine Department of Hematology and Oncology,30
已完成
2 期
Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell LymphomaStage I/II Extranodal NK/T-cell LymphomaNCT02276248Chinese Academy of Medical Sciences40
已完成
4 期
Treatment of Peripheral T-cell LymphomaPeripheral T-cell LymphomaNCT01664975Mingzhi Zhang100